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success. However, a comprehension of 21 randomised studies demon-
strated that intensiﬁed treatment is superior to standard in many studies, 
indicating the need of further studies (Tjan-Hejnen et al. Annals of 
Oncology (2002)13(10):1519).
Besides, what might happen if dose-dense treatment, higher doses and 
an extra drug were given at the same time? Is it possible to give? We 
started such a study six years ago but because of slow inclusion rate af-
ter 3 years, the study was stopped. Now we have evaluated the results.
Materials and methods. Our standard treatment (S) consisted of 6 
courses with carboplatin, 5 AUC and etoposide 100 mg/m2 iv day 1-3 
with 3 weeks interval. Thoracic radiotherapy was given 1.5 Gy bid to 
45 Gy to patients with LD, starting at course two. The intensiﬁed treat-
ment (I) consisted of carboplatin 6 AUC, etoposide 120 mg/m2 and Ifos-
famide 5000 mg/m2 course 1 and 3000 mg/m2 in course 2-6. Treatment 
was given with 2 weeks interval, and Neupogen was given to make 
avoid leucopenia. Radiotherapy was given in the same way as in S. 
Results: Two year survival was 5/7 (72%) in I and 4/11 (37%) in S. 
Five year survival was 4/7 (57%) in I and 3/11 (27%) in S. Now, after 
more than 5 years 4/7 are still alive in I and 2/11 (18%) in S. Trombocy-
topenia and fatigue was a greater problem in I, but leucopenia was not. 
Conclusion: We ﬁnd the results promising but not verifying a value 
of intensiﬁed treatment since there were too few patients to make the 
differences signiﬁcant. Therefore we plan to start a multicentric phase 
III study with the same treatment arms and with two year survival as 
the primary endpoint. Since we have a limited number of patients with 
SCLC, LD in Sweden we are very interested to come in contact with 
other groups, interested to test this option.
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Background: Small cell lung cancer (SCLC) is an aggressive malig-
nancy. The prognosis for the patients is very poor with metastases often 
present at the time of diagnosis. Despite the initial chemo-sensitivity 
the majority of the patients will relapse and die of their disease. Patient 
with Extensive Disease (ED) have a disappointing survival of 8-12 
weeks without chemotherapy and 8-11 months after proper treatment. 
Irinotecan, a topoisomerase I inhibitor, has been reported as an active 
new agent in SCLC. In combination with cisplatin, it has showed supe-
riority in response rates and progression free survival over the standard 
regimen of cisplatin and etoposide. We conducted a phase II study in 
order to evaluate the efﬁcacy and safety of Carboplatin, Irinotecan and 
Etoposide (CIE) combination in extensive-disease SCLC (ED-SCLC)
Patients and Methods: Forty six chemo-naïve patients with ED-SCLC 
and PS 0-2 were enrolled. Forty of them were men and 6 women. All of 
them were smokers and the median age was 59.6 years. We admin-
istered carboplatin AUC 5 on day 1, irinotecan 120/m2 on day 2 and 
etoposide 75mg/m2 on days 1,2,3 in a 21 days repeated cycles. The 
treatment was continued for up to 6 cycles. Response assessments were 
performed after cycles 3 and 6 and every 2 months subsequently. The 
patients were evaluated for response, survival and toxicity. Clinical (as 
site of metastasis) and laboratory (such as LDH) parameters were tested 
as prognostic factors for survival.
Results: Two hundred and two cycles were administered with an aver-
age of 4.5 cycle per patient. Overall response rate was 52.2% (partial 
and complete), mean overall survival was 16.3 months (CI: 95%: 13.0-
19.7) and there was an1 year survival rate of 43.47%.
Patients with brain metastasis had worse prognosis (P: 0.004). 
The three drug regimen was well tolerated. Only 1 patient had diarrhea 
grade II, 6 had grade III/IV and 1 patient was referred with abdominal 
pain. One was presented with fatal thrombocytopenia while two toxic 
deaths were reported. Nine patients (19.5%) had neutropenia grade 
III/IV, without being fatal, and 3 were presented with grade III anemia 
which need blood transfusions.
Conclusion: CIE regimen is effective and well tolerated for the treat-
ment of the poor prognosis group of ED-SCLC patients
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There is no reference second-line treatment for small-cell lung cancer 
(SCLC). The vital prognosis of these patients is poor and special atten-
tion must thus be paid both to quality of life and to economic issues. 
The aim of this phase II randomized trial (GFPC0501) is to compare, 
in patients with progressive SCLC after ﬁrst-line platinum-based che-
motherapy, oral multidrug chemotherapy (CCNU, cyclophosphamide, 
etoposide) and classical intravenous therapy with cyclophophamide, 
doxorubicine and vincristine (CAV regimen) in terms of tolerability, 
efﬁcacy (response rate, median one-year and overall survival times), 
quality of life and healthcare consumption. Based on a two-stage Briant 
and Day approach, the study will require a total of 138 patients, and the 
ﬁrst 38 patients will be included in an interim analysis. 
At this time, 41 had been enrolled by 16 centers (21 on oral multidrug 
therapy and 19 on CAV regimen).The results of the interim analysis 
will be available in June 2007 for a presentation at the IASCL meeting.
ClinicalTrials.gov: NCT00418743; 
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